The CDC found that the 2022-2023 influenza season had high severity among children and adolescents, resulting in them recommending that everyone receive the annual influenza vaccine by the end of October.
Based on previous seasons’ data, 2022-2023 was considered a high-severity influenza season for children and adolescents under the age of 18, according to the CDC’s Morbidity and Mortality Weekly Report.
Researchers explained that the CDC annually assesses the severity of each influenza season based on previous seasons, estimating the numbers and rates of influenza-associated medical visits, hospitalizations, and deaths in the United States. Consequently, the researchers’ report compared the impact of the 2022-2023 influenza season on children and adolescents to that of the 2016-2017 season through the 2021-2022 season; they excluded data from the 2020-2021 season as it was during the peak of the COVID-19 pandemic with minimal influenza activity.
To examine these areas, the CDC utilized 3 indicators:
The researchers explained that, for each severity indicator, they calculated the 50th, 90th, and 98th intensity thresholds (ITs) based on the mean of peak weekly values in previous seasons. They added that seasonal severity is classified as low if at least 2 of 3 indicators peak below IT50. On the other hand, it is classified as moderate, high, or very high if at least 2 of 3 indicators peak above IT50, IT90, or IT98, respectively.
Flu shot
Image credit: xtock - stock.adobe.com
From this study, the researchers classified the 2022-2203 influenza season for children and adolescents as high severity because the weekly percentage of outpatient visits for ILI, the influenza-associated hospitalization rate, and the percentage of deaths due to influenza all peaked between IT90 and IT98. Overall, rates of influenza-associated medical visits and hospitalizations among children and adolescents aged 5 to 17 years were higher during 2022-2023 than any season since 2016-2017.
Between October 1, 2022, and April 30, 2023, FluSurv-NET identified 2762 influenza-associated hospitalizations of patients younger than 18 years, 2108 of which they sampled. Similar to recent seasons, the researchers found the median (IQR) age of patients hospitalized to be 5 (2-9) years, 57.4% were male, and 50.5% had an underlying condition, the most common being asthma, obesity, and neurologic disorders. Notably, more than half of the 2022-2023 season’s total pediatric hospitalizations occurred between October and November 2022.
The researchers hypothesized that the high hospitalization rates during the 2022-2023 season occurred due to early influenza circulation before many patients had been vaccinated. Of those hospitalized that had data within FluSurv-NET, 18.3% received an influenza vaccine; this was much lower than other seasons where 35.8% to 41.8% of hospitalized patients were vaccinated. Additionally, of the symptomatic hospitalized patients, 64.9% received influenza antiviral treatment, which was lower than in prepandemic influenza seasons (80.8%-87.1%).
They also acknowledged their study’s limitations, one being that they based the severity assessments and incidence estimation adjustments for the frequency of influenza testing and other ratios on previous seasons’ data. Because of this, the data may not reflect current testing practices or care-seeking behaviors. Another limitation mentioned was that FluSurv-NET only covers approximately 9.0% of the US population, meaning that the characteristics of hospitalized children and adolescents may not be generalizable to all US pediatric hospitalizations.
Despite these limitations, the researchers noted that the study still demonstrated the high severity of the 2022-2023 influenza season among children and adolescents, as influenza-associated medical visits and hospitalizations met or exceeded those of previous seasons.
“Taken together, these findings underscore the importance of children and adolescents receiving a seasonal influenza vaccination, ideally by the end of October, and prompt influenza antiviral treatment for those who are hospitalized,” the authors wrote.
Reference
White EB, O’Halloran A, Sundaresan D, et al. High influenza incidence and disease severity among children and adolescents aged <18 years ― United States, 2022–23 season. MMWR Morb Mortal Wkly Rep. 2023;72:1108–1114. doi:10.15585/mmwr.mm7241a2.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More